Enrolling by invitationPhase 2NCT06410859

Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia

Studying Trigeminal neuralgia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
LKGS_277
Intervention
Botulinum Toxin Type A for Injection,also known as "HengLi®"(drug)
Enrollment
240 enrolled
Eligibility
18-75 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06410859 on ClinicalTrials.gov

Other trials for Trigeminal neuralgia

Additional recruiting or active studies for the same condition.

See all trials for Trigeminal neuralgia →

← Back to all trials